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Introduction
The UN Sustainable Development Goal 3 aims for a 
30% reduction in non-communicable diseases by 2030.1 
This aim will require substantial reductions in cardio-
vascular disease.2–4 Secondary prevention of recurrent 
myocardial infarction and stroke among those with 
known cardiovascular disease can reduce cardiovascular 
mortality substantially.2,3 The WHO Global Monitoring 
Framework for Non-Communicable Diseases aims for at 
least 50% coverage of those eligible with drug therapy 
and counselling by 2025.5
The cost-effectiveness of secondary prevention of 
cardiovascular disease, coupled with lifestyle changes, 
has long been established.4,6 Yet, the Prospective Urban 
Rural Epidemiology (PURE) study has demonstrated that 
within groups of countries categorised by income (low, 
lower-middle, upper-middle, and high), average use of 
drug treatment is low, particularly in the low-income 
countries,3 treatment is unavailable or unaffordable for 
many people,7 and its use is associated with wealth in 
south Asia8 and South America.9 Thus far, however, there 
are no comparisons of rates or extent of inequalities in 
the use of secondary prevention of cardio vascular disease 
across countries using consistent methods, and what 
data do exist are almost all from high-income countries. 
A recent systematic review10 identified ten studies that 
reported lower treatment rates among patients with 
lower social economic status. Only two studies looked 
beyond high-income countries, both set in China. One, 
which developed a composite measure of socioeconomic 
status based on education, income, occupation, and 
access to medical insurance, reported 43% lower use of 
aspirin and over 70% lower use of antiplatelet agents, 
statins, and β-blockers among patients with lower 
socioeconomic status.11 The other study examined 
inequalities by age, comparing patients older and 
younger than 65 years, finding lower use of secondary 
prevention in the former.12 Evidence on the level and 
distribution of secondary prevention at the country level 
is crucial for designing national health system policies 
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Summary
Background There is little evidence on the use of secondary prevention medicines for cardiovascular disease by 
socioeconomic groups in countries at different levels of economic development.
Methods We assessed use of antiplatelet, cholesterol, and blood-pressure-lowering drugs in 8492 individuals with 
self-reported cardiovascular disease from 21 countries enrolled in the Prospective Urban Rural Epidemiology (PURE) 
study. Defining one or more drugs as a minimal level of secondary prevention, wealth-related inequality was measured 
using the Wagstaff concentration index, scaled from –1 (pro-poor) to 1 (pro-rich), standardised by age and sex. 
Correlations between inequalities and national health-related indicators were estimated.
Findings The proportion of patients with cardiovascular disease on three medications ranged from 0% in South Africa 
(95% CI 0–1·7), Tanzania (0–3·6), and Zimbabwe (0–5·1), to 49·3% in Canada (44·4–54·3). Proportions receiving at 
least one drug varied from 2·0% (95% CI 0·5–6·9) in Tanzania to 91·4% (86·6–94·6) in Sweden. There was 
significant (p<0·05) pro-rich inequality in Saudi Arabia, China, Colombia, India, Pakistan, and Zimbabwe. Pro-poor 
distributions were observed in Sweden, Brazil, Chile, Poland, and the occupied Palestinian territory. The strongest 
predictors of inequality were public expenditure on health and overall use of secondary prevention medicines.
Interpretation Use of medication for secondary prevention of cardiovascular disease is alarmingly low. In many 
countries with the lowest use, pro-rich inequality is greatest. Policies associated with an equal or pro-poor distribution 
include free medications and community health programmes to support adherence to medications.
Funding Full funding sources listed at the end of the paper (see Acknowledgments). 
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that can reduce premature cardiovascular disease 
mortality and morbidity.
The objectives of this analysis are to use the PURE study 
data to produce the first estimates of socioeconomic 
inequality in the use of secondary prevention for 
cardiovascular disease within 21 countries at varying 
levels of development and to investigate health system 
factors that might be correlated with this inequality. We 
hypothesise that pro-rich inequality in the use of 
secondary prevention medicine for cardiovascular disease 
exists in some countries, and that this is associated with 
health system factors such as affordability of medicines 
and public expenditure on health care.
Methods
The PURE study
PURE is a large international study of the incidence, 
mortality, and risk factors associated with non-
communicable diseases,13 and includes individuals from 
urban and rural communities in 21 countries: Canada, 
Sweden, United Arab Emirates, Saudi Arabia, Argentina, 
Brazil, Chile, Malaysia, Poland, South Africa, Turkey, 
China, the Philippines, Colombia, Iran, the occupied 
Palestinian territory, Bangladesh, India, Pakistan, 
Zimbabwe, and Tanzania (in order of income, using 
2006 per capita gross domestic product [GDP] when the 
study was initiated).
Data collection in PURE has been described in detail 
elsewhere.13 Briefly, in each country, communities were 
selected to achieve a mix of rural and urban populations, 
while ensuring feasibility of data collection (eg, processing 
blood samples) and long-term follow-up. Households 
were selected to be broadly representative of the socio-
demographic composition of communities. Although 
not designed to be nationally representative, the socio-
demographic characteristics and death rates of the samples 
of the first 17 participating countries were similar to their 
national populations.14 Within each selected house-
hold, all individuals aged 35–70 years were eligible to 
participate. Each participant was interviewed using a 
standardised questionnaire and had a medical examination. 
Data included sociodemographic character istics, bio-
metrics, lifestyle, and behaviour, cardiovascular disease 
risk factors, health history, and the use of medications.13 
The years of data collection and the response rates for each 
country are in the appendix (pp 2, 3).
Ethics approval was acquired in each country from the 
local institutional ethical review board. All participants in 
the PURE study signed an informed consent form.
Procedures
Our population of interest comprises 8492 participants 
with known cardiovascular disease at recruitment. 
Cardiovascular disease was defined as self-reported 
myocardial infarction, coronary artery bypass graft 
surgery or percutaneous coronary angioplasty, angina, 
or stroke. Self-reports were verified against medical 
or hospital records in 455 reported events, with a 
confirmation rate of 89%.3 Use of medicines was defined 
by patient responses to the question: “List all the 
medications you are currently consuming at least once a 
week for the last month”. Self-reports of medicines being 
used were verified by asking patients to show the field 
workers their prescriptions or medical documents. 
We first investigated use of an optimal drug regimen 
for secondary prevention of cardiovascular disease, 
which includes an antiplatelet drug (aspirin, clopi-
dogrel, or other antiplatelet), cholesterol-lowering drug 
(statin, ezetimibe, or other cholesterol-lowering drug), a 
β-blocker, and an angiotensin-converting-enzyme inhibit-
 or or angiotensin-receptor blocker. Because the number 
of individuals with cardiovascular disease using the four-
drug regimen was very low in many countries, we 
examined inequality in the use of one or more drugs, 
which indicates a minimal level (although inadequate) 
secondary prevention of cardiovascular disease. Results 
for the use of two or more drugs are presented in the 
appendix (p 8).
Research in context
Evidence before this study
A systematic review of papers published between 1996 and 
2015, in English and German, on socioeconomic inequalities 
in access to treatment for cardiovascular disease found 
18 papers on secondary prevention, ten of which reported 
lower uptake in patients with lower socioeconomic status. 
Other research within the PURE study had examined 
inequalities in use of secondary prevention, but only using 
data combined from groups of countries defined by income or 
geographical region.
Added value of this study
This paper presents the first country-specific data on 
inequalities in use of secondary prevention for cardiovascular 
disease in countries at all levels of development and in all parts 
of the world. It reveals marked cross-country differences in the 
extent to which there is equitable utilisation among those with 
differing levels of wealth, and it points to potential 
explanations of these differences.
Implications of all the available evidence
Use of secondary prevention for cardiovascular disease is 
alarmingly low. Many of the countries with the lowest overall 
use also have the greatest pro-rich inequality in use. Countries 
with a pro-poor distribution have policies, such as free 
medications and community health programmes, to support 
adherence to medications that might improve secondary 
prevention of cardiovascular disease among the poor.
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Following asset-based approaches for measuring wealth 
employed in the Demographic and Health Surveys,15 the 
PURE study collected data on household possessions, 
including electricity supply and ownership of an auto-
mobile, other four-wheel vehicle, computer, tele vision, 
motorbike, livestock, refrigerator, washing machine, 
stereo, bicycle, kitchen mixer, telephone, land or real 
estate, and kitchen window.15 We used these data to 
generate an asset-based wealth index using principal 
components analysis within each country. This index 
places households within each country-specific sample 
on a continuous scale of relative wealth from poorest 
to richest.16 The index standardises the measurement of 
relative wealth across countries and enables meaningful 
cross-country comparisons.17 The distribution of wealth 
index scores for each country is shown in the appendix (p 4).
Statistical analysis
We provide an initial estimation of socioeconomic 
inequality in use of secondary prevention drugs for 
cardiovascular disease by comparing rates of medication 
use across wealth index tertiles of respondents with 
cardiovascular disease within each country. Rates were 
standardised for age and sex using logistic regression 
including a random effect to account for clustering at the 
community level.
Our measure of inequality in use over the entire 
socioeconomic distribution was the concentration index.18 
The concentration index is twice the covariance between a 
binary indicator of medication and (fractional) rank in the 
country-specific distribution of the wealth index (ie, 1/N 
for poorest, …, N/N for richest), divided by the mean rate 
of medication (for each country). If the use of secondary 
prevention drugs is not correlated with position in the 
wealth distribution, then the index is zero, indicating no 
socioeconomic inequality.
When applied to a binary variable, the range of the 
concentration index depends on the variable’s mean, 
which confounds comparison of inequality across 
countries with different rates of medication. Further, the 
ordering of countries by degree of inequality can depend 
on whether the index is used to measure inequality in the 
use of medication or in the non-use of medication. We 
avoided these limitations by using Wagstaff’s adjusted 
concentration index, which is simply the concentration 
index divided by 1 minus the mean rate of medication 
use (the same mean rate of medication used to calculate 
the concentration index).19 This index always lies in the 
range from –1 to 1, with a positive (or negative) value 
indicating disproportionate concentration of medication 
use among richer (or poorer) individuals. A value 
of 1 indicates that only the richest persons receive 
N Age (years) Women Prevalence of CVD 
Mean (SD) 95% CI n % 95% CI n % 95% CI
Canada 10 388 53·4 (9·2) 52·9–53·9 5576 53·7% 52·3–55·1 606 5·8% 5·0–6·8
Sweden 4151 52·7 (9·0) 51·7–53·6 2193 52·8% 51·5–54·2 163 3·9% 3·1–5·0
United Arab Emirates 1499 48·3 (10·1) 45·9–50·7 981 65·4% 59·6–70·8 72 4·8% 3·0–7·7
Saudi Arabia 2047 46·5 (9·1) 45·9–47·1 882 43·1% 41·3–44·8 69 3·4% 2·7–4·2
Argentina 7511 51·2 (9·8) 50·8–51·5 4612 61·4% 58·8–64·0 293 3·9% 3·4–4·5
Brazil 6076 52·1 (9·4) 51·0–53·2 3345 55·1% 50·4–59·6 418 6·9% 6·1–7·7
Chile 3512 51·8 (9·8) 50·0–53·5 2313 65·9% 61·7–69·8 115 3·3% 2·0–5·2
Malaysia 15 567 51·6 (9·6) 50·8–52·5 8712 56·0% 54·3–57·6 435 2·8% 2·4–3·3
Poland 1976 54·4 (9·2) 53·4–55·5 1235 62·5% 60·1–64·8 131 6·6% 3·1–13·6
South Africa 4486 49·1 (9·7) 47·5–50·7 2969 66·2% 59·9–72·0 212 4·7% 3·1–7·1
Turkey 4231 50·0 (9·1) 49·4–50·5 2553 60·3% 57·9–62·8 308 7·3% 6·3–8·4
China 47 119 51·1 (9·7) 50·3–51·9 27 449 58·3% 56·5–60·0 3464 7·4% 6·3–8·5
Philippines 4767 52·7 (9·6) 51·9–53·5 3401 71·3% 66·9–75·4 302 6·3% 5·4–7·4
Colombia 7499 50·8 (9·6) 50·2–51·4 4808 64·1% 61·1–67·0 282 3·8% 3·0–4·7
Iran 6013 48·5 (9·2) 47·5–49·5 3137 52·2% 44·4–59·8 359 6·0% 5·1–6·9
Occupied Palestinian 
territory
1644 49·2 (9·6) 48·6–49·9 803 48·8% 47·6–50·1 113 6·9% 5·5–8·5
Bangladesh 2926 46·0 (9·3) 45·4–46·6 1596 54·5% 52·9–56·2 80 2·7% 2·2–3·4
India 29 165 48·7 (10·4) 48·1–49·2 16 388 56·2% 54·2–58·2 773 2·7% 2·2–3·1
Pakistan 2397 47·4 (9·1) 46·0–48·7 1236 51·6% 47·8–55·3 126 5·3% 2·2–12·0
Zimbabwe 1220 51·4 (10·1) 48·3–54·6 821 67·3% 49·2–81·4 70 5·7% 2·3–13·4
Tanzania 1987 49·9 (11·3) 49·4–50·4 1518 76·4% 68·5–82·8 101 5·1% 2·8–9·0
All countries 166 181 50·6 (9·9) 50·3–50·9 96 528 58·1% 57·2–59·0 8492 5·1% 4·7–5·5
Countries are ordered by descending income level. *CVD is coronary artey disease or stroke.
Table 1: Proportion of individuals with cardiovascular disease (CVD)* reported at entry in the PURE study countries 
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medication. We confirmed the robustness of our findings 
to estimating inequality using the alternative Erreygers’ 
index20 that is less sensitive to very low and very high 
prevalence rates (appendix pp 5, 6).
Using the fact that a concentration index is a function 
of the covariance between an indicator of medicine use 
and (fractional) rank in the distribution of wealth, it is 
calculated (for each country) from a convenient least 
squares regression.18 Individual-level data were used. 
There was no grouping. SEs were obtained by the delta 
method applied to a non-linear function of the least 
squares coefficients, which is equal (by definition) to 
the concentration index, and adjusted for arbitrary 
correlation within communities, and heteroscedasticity 
of general form. Wagstaff’s adjusted concentration index 
values were indirectly standardised for differences in age 
and sex (within each country) across the distribution of 
the wealth index. The model used to standardise the 
concentration indices is included in the appendix (p 7).
We hypothesised that increasing availability and 
affordability in a country will be associated with more 
equal use. We plotted values of Wagstaff’s adjusted 
concentration index for each country against six measures 
related to availability and affordability of treatment in a 
country: overall rate of use of at least one secondary 
prevention drug, which acts as an indicator of availability 
and affordability combined; proportion of pharmacies in 
the community where all four secondary prevention 
medicines (ie, antiplatelet agent, statin, β-blocker, and one 
drug acting on the angiotensin system) are available; 
proportion of the sample for whom the price of all four 
secondary prevention drugs combined is unaffordable 
(defined as costing more than 20% of household income 
net of food expenditure7); gross national income per capita, 
adjusted for purchasing power parity; public expenditure 
on health as a proportion of GDP; and out-of-pocket 
expenditure on health. We use Kendall’s rank correlation 
coefficient (Kendall’s tau) to measure the strength and 
direction of the association between each of these variables 
and Wagstaff’s adjusted concentration index. Kendall’s tau 
coefficient (τ) is defined as: ([number of concordant 
pairs] – [number of discordant pairs]) / (n[n – 1] / 2). Data on 
overall use were obtained from the PURE study; data 
on availability and costs of medicines were from the 
linked Environmental Profile of a Community’s Health 
instrument (details are included in the appendix, p 7);21 
data on gross national income, public expenditure, and 
out-of-pocket expenditure were obtained from the World 
Bank Development Indicators database22 (using indicators 
for each country for the most recent year of data collection 
in that country; appendix, p 7). All analyses were done in 
Stata version 14.
Role of the funding source
The funders of the study had no role in its design, data 
collection, data analysis, data interpretation, writing of 
the report, or in the decision to submit the paper for 
publication. The lead and senior authors (AM and MM) 
had full access to all the data in the study and all authors 
had final responsibility for the decision to submit for 
publication.
Results
The countries with the highest rates of cardiovascular 
disease were China (7·4%, 95% CI 6·3–8·5) and 
Turkey (7·3%, 6·3–8·4). Countries with the lowest rates 
of cardiovascular disease were India (2·7%, 95% CI 
2·2–3·1) and Bangladesh (2·7%, 2·2–3·4; table 1).
The proportion of participants with cardiovascular 
disease who were taking three or more secondary 
prevention medications ranged from 0% in South 
Africa (95% CI 0–1·7), Tanzania (0–3·6), and 
Zimbabwe (0–5·1), to 49·3% (44·4–54·3) in Canada. The 
proportions using at least one drug for secondary 
prevention are higher, but vary significantly from 
2·0% (95% CI 0·5–6·9) in Tanzania to 91·4% (86·6–94·6) 
in Sweden (table 2). The proportion of people with 
cardiovascular disease using each individual type of 
cardiovascular disease secondary prevention medicine is 
shown in table 3.
From our sample of those with cardiovascular disease, 
5·7% of individuals were missing data on household 
Three or more secondary 
prevention drugs
One or more secondary 
prevention drugs
N % 95% CI N % 95% CI
Canada 299 49·3% 44·4–54·3 546 90·1% 87·7–92·1
Sweden 72 44·2% 35·2–53·6 149 91·4% 86·6–94·6
United Arab 
Emirates
28 38·9% 22·2–58·7 61 84·7% 71·8–92·4
Saudi Arabia 17 24·6% 10·8–47·0 50 72·5% 56·7–84·1
Argentina 25 8·5% 4·8–14·7 222 75·8% 70·4–80·5
Brazil 69 16·5% 11·7–22·7 337 80·6% 77·2–83·6
Chile 11 9·6% 2·1–34·2 70 60·9% 29·1–85·5
Malaysia 33 7·6% 4·3–13·1 152 34·9% 25·1–46·3
Poland 35 26·7% 22·7–31·2 112 85·5% 80·1–89·6
South Africa 0 0·0% 0·0–1·7 56 26·4% 16·2–40·0
Turkey 37 12·0% 9·3–15·5 195 63·3% 56·2–69·9
China 32 0·9% 0·6–1·4 1435 41·4% 36·7–46·3
Philippines 7 2·3% 1·1–4·6 186 61·6% 53·3–69·2
Colombia 30 10·6% 6·6–16·7 150 53·2% 45·0–61·2
Iran 69 19·2% 14·5–25·1 263 73·3% 67·9–78·0
Occupied 
Palestinian 
territory
23 20·4% 13·2–30·1 98 86·7% 79·1–91·9
Bangladesh 1 1·3% 0·2–8·8 14 17·5% 9·0–31·3
India 19 2·5% 1·0–5·7 186 24·1% 16·8–33·2
Pakistan 1 0·8% 0·1–9·5 34 27·0% 5·0–72·3
Zimbabwe 0 0·0% 0·0–5·1 22 31·4% 5·9–76·9
Tanzania 0 0·0% 0·0–3·6 2 2·0% 0·5–6·9
Countries are ordered by descending income level.
Table 2: Use of secondary prevention medicines among those reporting 
cardiovascular disease in the PURE study
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wealth. These individuals were excluded from inequality 
analyses and information. Missing data on household 
wealth by country is shown in the appendix (p 9). All 
other variables used in the analysis were complete. The 
proportion of individuals using at least one drug among 
those with cardiovascular disease was higher in the 
richest wealth index tertile than in the poorest tertile in all 
countries except Canada, Sweden, Brazil, Chile, Poland, 
Malaysia, and the occupied Palestinian territory, where it 
was either similar in the richest and poorest groups, or 
higher among the poorest. In Pakistan, use of at least one 
drug was 18·6 times higher among the richest tertile than 
among the poorest tertile (57·7% vs 3·1%); in India, it was 
6·2 times higher (28·7% vs 4·6%), and in Zimbabwe 3·8 
times higher (53·1% vs 13·9%; figure 1).
Wagstaff’s adjusted concentration index values for use 
of at least one medication are shown in table 4. Negative 
Wagstaff’s adjusted concentration index values indicate 
greater use among the poor (pro-poor), whereas positive 
values indicate pro-rich distribution of medication use. 
There was significant (at the 5% level) pro-rich inequality 
in Saudi Arabia, China, Colombia, India, Pakistan, and 
Zimbabwe. Wagstaff’s adjusted concentration index 
values suggested a pro-poor distribution of use of 
minimum medication for cardiovascular disease in 
Sweden, Chile, Poland, and the occupied Palestinian 
territory, but none of these estimates were significant.
There is a significant inverse association between the 
measure of socioeconomic inequality and the proportion 
of those using at least one secondary prevention drug. 
Countries that rank higher in terms of average use of at 
least one cardiovascular disease medication rank lower 
in the degree to which utilisation is pro-rich (Wagstaff’s 
adjusted concentration index–mean rate: Kendall’s tau 
[τ ]=–0·5524; p=0·001; figure 2A). Plots of each country’s 
Wagstaff’s adjusted concentration index against 
availability (τ=–0·4190; p=0·007) and affordability of 
medicines (τ=0·4000; p=0·012), gross national income 
per capita (τ=–0·3714; p=0·020), public expenditure 
on health as a proportion of GDP (τ=–0·4762; p=0·003), 
and out-of-pocket payment as a proportion of total 
health expenditure (τ=0·1429; p=0·381) are shown in 
figure 2B–F. Of the factors plotted, the strongest 
predictors of variation in inequality among countries are 
overall secondary prevention use (R²=0·4743) and public 
expenditure on health as a proportion of GDP 
(R²=0·4291).
Discussion
To our knowledge, this study is the first to present 
estimates of the rate of, and inequality in, secondary 
prevention of cardiovascular disease in individual 
countries at various levels of development. Our results 
reveal alarmingly low use of optimal secondary prevention 
of cardiovascular disease in many countries. Whereas the 
lowest use was observed in low-income and middle-
income countries, specifically South Africa, Tanzania, and 
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Zimbabwe, even the high-income countries included in 
our study have not reached the modest target of 
50% coverage of drug therapy with three of the four drugs 
set out in the WHO Global Monitoring Framework for 
Non-Communicable Diseases.5 This target includes 
patients with no previous cardiovascular disease event 
but at more than 30% risk of experiencing one within 
10 years, who are excluded from our study. So, we are 
likely to underestimate the challenge ahead. Although the 
low overall rates we observed in high-income countries 
such as Canada might be surprising, they are consistent 
with findings from the USA,23 and reinforce the need for 
greater efforts to reach WHO targets for reduction of 
cardiovascular disease mortality by addressing treatment 
gaps in all countries, not only in low-income countries.
In several countries in our study, the situation is much 
worse for the poorest, with significant pro-rich inequality 
in the use of at least one drug observed in China, 
Saudi Arabia, Colombia, India, Pakistan, and Zimbabwe. 
The findings from China are consistent with recent 
evidence of unaffordability of cardiovascular disease drugs; 
for example, the cost of a month’s supply of a generic 
brand of atorvastatin (a cholesterol-lowering drug) is 
equivalent to 6·7 days’ wages of the lowest paid government 
workers.24 Another study from China found lower use of 
secondary prevention among older people with less 
education and younger people with lower incomes.12
We found greater socioeconomic inequality in the use 
of drugs in countries with lower mean use of secondary 
prevention medicines. This finding is consistent with the 
inverse equity hypothesis25,26 that medical technologies are 
initially used to a greater extent by the socially privileged 
and inequalities only begin to fall once the needs of the 
rich are met. One potential policy response is to 
concentrate on raising the average rate of medication use 
by securing universal access without targeting any 
particular group. At least in theory, relative disparities 
should narrow as long as all groups benefit and none fall 
through the net. This approach is simpler and might be 
cheaper than identifying those with greatest unmet need. 
But it is important to ensure that this is working as 
intended because, otherwise, there is a risk of reinforcing 
existing gaps in medicine use. By contrast, “progressive 
universalism”27 that targets resources on those with 
greatest unmet need within a system promoting universal 
access to essential treatment might achieve the greatest 
reduction in avoidable deaths while simultaneously 
reducing inequities.
Left unaddressed, these inequalities in treatment use 
will ultimately exacerbate inequalities in cardiovascular 
disease.28–30 Yet, the inequality we have observed is not 
inevitable. Our scatter plots provide insight into factors 
that might explain part of the cross-country variation in 
inequality. Some variation is explained by availability and 
affordability of secondary prevention medications in the 
studied communities. This finding is consistent with our 
earlier work showing that, although drugs for secondary 
prevention of cardiovascular disease are licensed and 
distributed in all countries in this study, in both branded 
Figure 1: High-low plot showing the 95% confidence range for the use of at least one secondary prevention 
drug by wealth tertile in the PURE study countries
Countries are ordered by 2006 per capita gross domestic product. Countries with significant p values for the 
hypothesis test that the absolute difference in adjusted prevalence between the richest and poorest tertiles is equal 
to zero: China, p=0·0259; Colombia, p=0·0002; Bangladesh, p=0·0025; India, p=0·0000; Pakistan, p=0·0006; and 
Zimbabwe, p=0·0066. 
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Poorest tertile
Middle tertile
Richest tertile
Estimate SE 95% CI
Canada 0·0202 0·0801 –0·1368 to 0·1772
Sweden –0·0210 0·1563 –0·3274 to 0·2855
United Arab Emirates 0·1979 0·1828 –0·1603 to 0·5562
Saudi Arabia* 0·3278 0·1623 0·0097 to 0·6458
Argentina 0·0320 0·0784 –0·1217 to 0·1857
Brazil –0·0258 0·0698 –0·1626 to 0·1110
Chile –0·0749 0·0944 –0·2600 to 0·1102
Malaysia 0·0634 0·0589 –0·0521 to 0·1788
Poland –0·0592 0·1445 –0·3423 to 0·2240
South Africa 0·1383 0·0920 –0·0420 to 0·3186
Turkey 0·1070 0·0649 –0·0202 to 0·2341
China* 0·1342 0·0200 0·0949 to 0·1734
Philippines 0·1201 0·0706 –0·0182 to 0·2584
Colombia* 0·2187 0·0620 0·0972 to 0·3403
Iran 0·0373 0·0659 –0·0918 to 0·1664
Occupied Palestinian 
territory
–0·0490 0·1470 –0·3371 to 0·2391
Bangladesh 0·2662 0·1745 –0·0757 to 0·6081
India* 0·4841 0·0516 0·3830 to 0·5853
Pakistan* 0·6231 0·1069 0·4136 to 0·8325
Zimbabwe* 0·3550 0·1507 0·0596 to 0·6504
Tanzania 0·3667 0·4786 –0·5714 to 1·3048
*Statistically significantly pro-rich at 5% level. Positive=pro-rich. Negative=pro-poor.
Table 4: Adjusted Wagstaff concentration indices for use of at least one 
secondary prevention medication, by country in the PURE study
Articles
www.thelancet.com/lancetgh   Vol 6   March 2018 e298
and generic forms, they are less likely to be stocked by 
retailers based in rural and poor communities.7 A further 
problem is that people living in our rural communities 
might have to travel much longer distances to reach a 
pharmacy. It is also consistent with evidence from other 
low-income and middle-income countries, which suggests 
that the costs of cardiovascular disease medication are 
a major contributor to risks of catastrophic medical 
expenditure and a barrier to treatment, especially among 
the poorest,31–33 suggesting that in countries without 
universal health coverage, poverty negatively affects access 
to medicines for coronary heart disease.10 More research is 
needed on the extent of the economic burden imposed by 
chronic treatment costs for cardiovascular disease on poor 
households in a wider range of countries,34 and the impact 
that this burden has on their decision to adhere to care.
Figure 2: Scatter plots of Wagstaff concentration index of inequality in secondary prevention use against national-level and community-level health system 
factors
(A) Use of at least one secondary prevention drug, (B) availability and (C) affordability of medicines, (D) gross national income per capita, (E) public expenditure on 
health as a proportion of GDP, and (F) out-of-pocket payment as a proportion of total health expenditure. ARG=Argentina. BGD=Bangladesh. BRA=Brazil. 
CAN=Canada. CHL=Chile. CHN=China. COL=Colombia. IND=India. IRN=Iran. MYS=Malaysia. OPT=occupied Palestinian territory. PAK=Pakistan. PHL=Philippines. 
POL=Poland. SAU=Saudi Arabia. SWE=Sweden. TUR=Turkey. TZA=Tanzania. UAE=United Arab Emirates. ZAF=South Africa. ZWE=Zimbabwe. GNI=gross national 
income. GDP=gross domestic product. PPP=purchasing power parity. Int$=international dollar, adjusted for purchasing power parity.
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Aside from the mean use of secondary prevention of 
cardiovascular disease, the strongest predictor of inequality 
in use was public expenditure on health as a proportion of 
GDP. A recent report from the Chatham House Centre on 
Global Health Security35 concluded that in order for 
countries to achieve minimum standards of health-care 
access and financial protection, public (or government) 
health expenditure as a proportion of GDP should be at 
least 5%. Among those countries in our study, this target 
is only reached in Canada (7·9%), Sweden (8·1%), 
Argentina (5·0%), Poland (5·1%), Colombia (5·1%), and 
the occupied Palestinian territory (6·8%; Turkey 
spends 4·9%).22 The target for government spending is 
only one aspect of a comprehensive financing framework.35 
It must be combined with policies to ensure that health 
care is delivered efficiently to those who need it, addressing 
patient-level barriers, such as lack of health literacy or 
awareness of the importance of treatment adherence.10,33,36 
Recent evidence suggests that the polypill (combination 
pill including three or four of the secondary prevention 
drug types) might improve adherence.37
Brazil might provide one example of a successful policy 
approach to reducing inequality in preventive and 
primary care. Most common medications are free at the 
point of service for all citizens. Additionally, the country’s 
Family Health Strategy uses a community-based 
approach to improve access to primary health care for 
previous underserved populations, including extensive 
use of community health workers to support patients in 
adhering to medication regimens.38 Evidence has shown 
that the poorest municipalities in Brazil have particularly 
benefited from the Family Health Strategy39 and the 
programme is associated with reductions in cardi-
ovascular disease mortality and hospitalisations.40
Our study has some limitations. First, samples were not 
selected to be nationally representative and the numbers 
with cardiovascular disease are low in some countries, 
limiting scope for disaggregated analyses and resulting in 
large error margins for our estimates from some countries. 
While the samples are similar to the national population in 
respect of major demographic and socio economic 
characteristics,14 one criterion for selection of communities 
was that they facilitated long-term follow-up. Hence, 
extremes of the economic spectrum, especially the lower 
bound, are probably excluded. While this will probably 
lead to underestimates of use of secondary prevention and 
wealth-related inequality, our estimates should be 
interpreted with caution and followed up with further 
country-specific research. As mentioned, a small 
percentage of our sample of individuals with cardiovascular 
disease was also excluded from our analysis due to missing 
data. We do not impute for these missing wealth data and 
these observations are excluded from our analyses, which 
assumes that missing wealth data is completely at random 
in all countries. This assumption might bias our inequality 
estimates, although the direction of that bias is unclear. 
Second, our data rely on self-reported coronary heart 
disease and stroke, and are therefore potentially vulnerable 
to bias. However, as discussed above, self-reports were 
verified against medical or hospital records in 455 reported 
events, with a confirmation rate of 89%, and available data 
from other studies of stroke and myocardial infarction 
support the accuracy of self-reports.41–44 Third, our data are 
cross-sectional and we cannot determine whether 
participants are prescribed and commenced on secondary 
prevention and then cease using the medication, or 
whether they are never prescribed the medication; nor can 
we tell whether they are using the medication as prescribed 
(eg, daily vs weekly). For example, one study using registry 
data from India found that about half of all patients 
suffering a myocardial infarction were discharged on 
secondary prevention but adherence declined rapidly.45 
Fourth, quantitative analyses reveal but do not explain 
socioeconomic inequality. The next step requires 
multidisciplinary research to understand observed 
variations, as in earlier studies of hypertension in 
Malaysia46 and Colombia.47 Fifth, we do not know the 
reasons why individuals were using medicines. Thus, 
some might have been initiated to treat hypertension 
rather than explicitly for secondary prevention. We might, 
therefore, be seeing an effect of varying local practices and 
guidelines for hypertension. For example, in South Africa, 
initial treatment with diuretics or calcium channel blockers 
(or both) is recommended for black patients because they 
are more effective in this population than angiotensin-
converting-enzyme inhibitors.48 However, regardless of 
whether the blood-pressure-lowering drug being used by 
the individual with cardiovascular disease was initially 
prescribed for hypertension, what is important is that this 
individual is taking secondary prevention medication, and 
therefore has the ability to benefit from it. Finally, it is 
possible that in some countries where health-care reforms 
have been implemented recently, such as Iran, our data fail 
to capture resulting increases in secondary prevention use.
Secondary prevention medicines are highly effective in 
avoiding recurrence of cardiovascular disease events, 
which can be especially devastating for people living in 
low-income and middle-income countries where acute, 
life-saving treatment might not be easily available and 
the economic consequences of illness are severe. Our 
findings revealed both remarkably low rates of use of 
known effective secondary prevention medications in 
several countries, but also statistically significant 
inequality in some low-income and middle-income 
countries. The UN and WHO have now recognised the 
need to reduce the burden of non-communicable 
diseases, including cardiovascular diseases, and to 
narrow inequalities in premature mortality. To realise 
these goals, increased and more equitable secondary 
prevention must be high on the agenda.
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